S. 4120 

One Hundred Seventeenth Congress 

of the 

United States of America 

AT THE SECOND SESSION 

Begun and held at the City of Washington on Monday, 

the third day of January, two thousand and twenty two 

An Act 

To maximize discovery, and accelerate development and availability, of promising 

childhood cancer treatments, and for other purposes. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. SHORT TITLE. 

This Act may be cited as the ‘‘Childhood Cancer Survivorship, 

Treatment, Access, and Research Reauthorization Act of 2022’’ or 

the ‘‘Childhood Cancer STAR Reauthorization Act’’. 

SEC. 2. REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT. 

(a) CHILDREN’S CANCER BIOREPOSITORIES.—Section 417E of the 

Public Health Service Act (42 U.S.C. 285a–11) is amended— 

(1) in subsection (a)— 

(A) in paragraph (2)(A), by inserting before the period 

at the end of the second sentence the following: ‘‘, such 

as collected samples of both solid tumor cancer and paired 

samples’’; 

(B) in paragraph (9), by striking ‘‘Childhood Cancer 

Survivorship, Treatment, Access, and Research Act of 2018’’ 

and inserting ‘‘Childhood Cancer Survivorship, Treatment, 

Access, and Research Reauthorization Act of 2022’’; 

(C) by redesignating paragraph (10) as paragraph (11); 

and 

(D) by inserting after paragraph (9) the following: 

‘‘(10) REPORT ON RESEARCHER ACCESS TO CHILDREN’S

CANCER BIOREPOSITORY SAMPLES.—Not later than 2 years after 

the date of enactment of the Childhood Cancer Survivorship, 

Treatment, Access, and Research Reauthorization Act of 2022, 

the Director of NIH shall— 

‘‘(A) conduct a review of the procedures established 

under paragraph (2)(C) and other policies or procedures 

related to researcher access to such biospecimens to identify 

any opportunities to reduce administrative burden, consistent with paragraph (2)(D), in a manner that protects 

personal privacy to the extent required by applicable Federal and State privacy law, at a minimum; and 

‘‘(B) submit to the Committee on Health, Education, 

Labor, and Pensions of the Senate and the Committee 

on Energy and Commerce of the House of Representatives 

a report on the findings of the review under subparagraph 

(A) and whether the Director of NIH plans to make any 

changes to the policies or procedures considered in such 

review, based on such findings.’’; and 
S. 4120—2 

(2) in subsection (d), by striking ‘‘2019 through 2023’’ and 

inserting ‘‘2024 through 2028’’. 

(b) CANCER SURVIVORSHIP PROGRAMS.—Section 201 of the 

Childhood Cancer Survivorship, Treatment, Access, and Research 

Act of 2018 (Public Law 115–180) is amended— 

(1) in subsection (a)— 

(A) in the subsection heading, by striking ‘‘PILOT PROGRAMS TO EXPLORE’’ and inserting ‘‘RESEARCH TO

EVALUATE’’ 

(B) in paragraph (1)— 

(i) by striking ‘‘may make awards to eligible entities to establish pilot programs’’ and inserting ‘‘shall, 

as appropriate, make awards to eligible entities to 

conduct or support research’’; 

(ii) by striking ‘‘model systems’’ and inserting 

‘‘approaches’’; 

(iii) by inserting ‘‘and adolescent’’ after ‘‘childhood’’; 

and 

(iv) by striking ‘‘evaluation of models for’’; 

(C) in paragraph (2)— 

(i) in subparagraph (A), in the matter preceding 

clause (i), by inserting ‘‘within the existing peer review 

process,’’ after ‘‘practicable,’’; and 

(ii) in subparagraph (B)(v), by striking ‘‘in treating 

survivors of childhood cancers’’ and inserting ‘‘in carrying out the activities described in paragraph (1)’’; 

and 

(D) in paragraph (3)(B)(v), by striking ‘‘design of systems for the effective transfer of treatment information 

and care summaries from cancer care providers to other 

health care providers’’ and inserting ‘‘design tools to support the secure electronic transfer of treatment information 

and care summaries between health care providers or, as 

applicable and appropriate, longitudinal childhood cancer 

survivorship cohorts’’; and 

(2) in subsection (b)— 

(A) in each of paragraphs (1) and (2), by striking ‘‘date 

of enactment of this Act’’ and inserting ‘‘date of enactment 

of the Childhood Cancer Survivorship, Treatment, Access, 

and Research Reauthorization Act of 2022’’; and 

(B) in paragraph (1)— 

(i) by striking subparagraphs (A) and (C); 

(ii) by redesignating subparagraph (B) as subparagraph (A); and 

(iii) by adding at the end the following: 

‘‘(B) recommendations for enhancing or promoting 

activities of the Department of Health and Human Services 

related to workforce development for health care providers 
S. 4120—3 

who provide psychosocial care to pediatric cancer patients 

and survivors.’’. 

Speaker of the House of Representatives. 

Vice President of the United States and

President of the Senate.